MyoKardia, Inc.

333 Allerton Avenue
South San Francisco
United States

Tel: 650-741-0900


Show jobs for this employer

About MyoKardia, Inc.

MyoKardia’s mission is to change the world for patients with serious cardiovascular disease through bold and innovative science. 
MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has generated a pipeline of therapeutic programs for the chronic treatment of two of the most prevalent forms of heritable cardiomyopathy – hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). MyoKardia’s most advanced product candidate is mavacamten, a novel, oral, allosteric modulator of cardiac myosin intended to reduce hypercontractility. Mavacamten is being studied in a pivotal Phase 3 clinical trial, known as EXPLORER-HCM, in patients with symptomatic, obstructive HCM. MyoKardia is also conducting the MAVERICK-HCM trial of mavacamten in non-obstructive HCM. MYK-491, MyoKardia’s second product candidate, is designed to increase the overall extent of the heart’s contraction in DCM patients by increasing cardiac contractility. MyoKardia's ongoing research and drug discovery efforts are focused on targeting excessive contraction, impaired relaxation and insufficient contraction. Founded in September 2012 MyoKardia is headquartered in South San Francisco, CA.

Stock Symbol: MYOK

Stock Exchange: NASDAQ


77 articles with MyoKardia, Inc.